Marinus Pharmaceuticals (NASDAQ:MRNS) Given “Buy” Rating at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH reissued their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Monday, AnalystRatings.com reports. The firm currently has a $5.00 target price on the biopharmaceutical company’s stock.

A number of other analysts have also issued reports on the company. Cantor Fitzgerald reissued an overweight rating and issued a $7.00 target price on shares of Marinus Pharmaceuticals in a research report on Friday, October 18th. HC Wainwright reissued a buy rating and issued a $5.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, November 13th. Zacks Investment Research lowered Marinus Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, November 12th. ValuEngine lowered Marinus Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, November 1st. Finally, Mizuho cut their target price on Marinus Pharmaceuticals from $5.00 to $1.70 and set a neutral rating on the stock in a research report on Tuesday, July 23rd. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Marinus Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $8.65.

NASDAQ MRNS traded down $0.05 on Monday, reaching $1.04. The stock had a trading volume of 490,600 shares, compared to its average volume of 955,644. The firm has a market capitalization of $58.72 million, a price-to-earnings ratio of -1.16 and a beta of 2.82. Marinus Pharmaceuticals has a 12-month low of $0.77 and a 12-month high of $6.00. The stock has a fifty day moving average price of $1.28 and a two-hundred day moving average price of $2.54.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). On average, sell-side analysts expect that Marinus Pharmaceuticals will post -0.96 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of MRNS. BlackRock Inc. increased its position in shares of Marinus Pharmaceuticals by 7.2% during the second quarter. BlackRock Inc. now owns 3,427,739 shares of the biopharmaceutical company’s stock worth $14,226,000 after acquiring an additional 229,811 shares during the period. Morgan Stanley increased its position in shares of Marinus Pharmaceuticals by 1,679.6% during the second quarter. Morgan Stanley now owns 187,889 shares of the biopharmaceutical company’s stock worth $780,000 after acquiring an additional 177,331 shares during the period. Vanguard Group Inc. increased its position in shares of Marinus Pharmaceuticals by 4.7% during the second quarter. Vanguard Group Inc. now owns 2,587,314 shares of the biopharmaceutical company’s stock worth $10,737,000 after acquiring an additional 115,294 shares during the period. Wells Fargo & Company MN increased its position in shares of Marinus Pharmaceuticals by 199.6% during the second quarter. Wells Fargo & Company MN now owns 52,642 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 35,072 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Marinus Pharmaceuticals by 32.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 126,761 shares of the biopharmaceutical company’s stock worth $527,000 after acquiring an additional 31,260 shares during the period. 54.63% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Story: Dividend Aristocrat Index

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.